Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium

Toxicology

Volumn 249, Issue 1, 2008, Pages 85-90

  Singh, Maneesh N ^a,b   Stringfellow, Helen F ^a   Walsh, Michael J ^b   Ashton, Kate M ^a   Paraskevaidis, Evangelos ^c   Abdo, Khalil R ^a   Martin Hirsch, Pierre L ^a   Phillips, David H ^d   Martin, Francis L ^b  

^a LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF IOANNINA   (Greece)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

CYP3A4; Endometrial carcinoma; Genotoxic; Selective oestrogen receptor modulator; SULT2A1; Tamoxifen

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; MESSENGER RNA; TAMOXIFEN;

ARTICLE; CATALYSIS; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; EPITHELIUM TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; CARCINOMA; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; RNA, MESSENGER; SULFOTRANSFERASES; TAMOXIFEN;

EID: 44649149538     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2008.04.009     Document Type: Article

References (50)

1. Apak T.I., and Duffel M.W. Interactions of the stereoisomers of α-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab. Dispos. 32 (2004) 1501-1508
2. Axelrod J., and Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233 (1958) 702-705
3. 32P-postlabeling analyses of tamoxifen-DNA adducts in humans. J. Natl. Cancer Inst. 96 (2004) 1099-1104
4. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
5. Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E., Perlman J.A., and Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 99 (1999) 1654-1662
6. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., and White I.N. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23 (2002) 1897-1901
7. 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20 (1999) 339-342
8. Chu W., Fyles A., Sellers E.M., McCready D.R., Murphy J., Pal T., and Narod S.A. Association between CYP3A4 genotype and risk of endometrial cancer following tamoxifen use. Carcinogenesis 28 (2007) 2139-2142
9. Curtis R.E., Boice Jr. J.D., Shriner D.A., Hankey B.F., and Fraumeni Jr. J.F. Second cancers after the adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88 (1996) 832-834
10. Curtis R.E., Freedman D.M., Sherman M.E., and Fraumeni Jr. J.F. Risk of mixed mullerian tumours after tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 96 (2004) 70-74
11. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., and Boyle P. Overview of the main outcomes in breast cancer prevention trials. Lancet 361 (2003) 296-300
12. Dallenbach-Hellweg G., Schmidt D., Hellberg P., Bourne T., Kreuzwieser E., Dören M., Rydh W., Rudenstam G., and Granberg S. The endometrium in breast cancer patients on tamoxifen. Arch. Gynecol. Obstet. 263 (2000) 170-177
13. Davis W., Venitt S., and Phillips D.H. The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19 (1998) 861-866
14. Dawling S., Roodi N., Mernaugh R.L., Wang X., and Parl F.F. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 61 (2001) 6716-6722
15. Fisher B., Constantino J.P., Redmond C.K., Wickerman D.L., and Cronin W.M. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
16. Fisher B., Constantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., and Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 97 (2005) 1652-1662
17. Glatt H.R., Davis W., Meinl W., Hermersdörfer H., Venitt S., and Phillips D.H. Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19 (1998) 1709-1713
18. Greaves P., Goonetilleke R., Nunn G., Topham J., and Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53 (1993) 3919-3924
19. Han X., and Liehr J.G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52 (1992) 1360-1363
20. Hashiba M., Kasahara T., Kim S.Y., Shibutani S., and Degawa M. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Cancer Sci. 97 (2006) 468-477
21. Hukkanen J., Mäntylä M., Kangas L., Wirta P., Hakkola J., Paakki P., Evisalmi S., Pelkonen O., and Raunio H. Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82 (1998) 93-97
22. Katzenellenbogen B.S. Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod. 54 (1996) 287-293
23. Kendall A., Folkerd E.J., and Dowsett M. Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J. Steroid Biochem. Mol. Biol. 103 (2007) 99-109
24. Lee A.J., Cai M.X., Thomas P.E., Conney A.H., and Zhu B.T. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144 (2003) 3382-3398
25. Liehr J.G. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum. Reprod. Update 7 (2001) 273-281
26. MacMahon B. Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin. Oncol. 24 (1997) S1-122-S1-39
27. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11 (1993) 485-490
28. Mahadevan B., Arora V., Schild L.J., Keshava C., Cate M.L., Iversen P.L., Poirier M.C., Weston A., Pereira C., and Baird W.M. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology. Mol. Carcinog. 45 (2006) 118-125
29. Martin F.L. Complex mixtures that may contain mutagenic and/or genotoxic components: a need to assess in vivo target-site effect(s) associated with in vitro-positive(s). Chemosphere 69 (2007) 841-848 10.1016/j.chemosphere.2007.05.066
30. McGrath M., Hankinson S.E., Arbeitman L., Colditz G.A., Hunter D.J., and De Vivo I. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25 (2004) 559-565
31. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.F., Cutuli B., Lasry S., Mauriac L., Granon C., Kerr C., Giard S., Hill C., de Lafontan B., de Gislain C., D'Anjou J., Fondrinier E., Lefeuvre C., Parache R.M., and Chauvin F. Iatrogenic risks of endometrial cancer after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int. J. Cancer 76 (1998) 325-330
32. Nutter L.M., Ngo E.O., and Abul-Hajj Y.J. Characterisation of DNA damage induced by 3,4-estrone-o-quinone in human cells. J. Biol. Chem. 266 (1991) 16380-16386
33. Osborne M.R., Hewer A., Hardcastle I.R., Carmichael P.L., and Phillips D.H. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56 (1996) 66-71
34. Osborne M.R., Davis W., Hewer A.J., Hardcastle I.R., and Phillips D.H. 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem. Res. Toxicol. 12 (1999) 151-158
35. Phillips D.H., Hewer A., Horton M.N., Cole K.J., Carmichael P.L., Davis W., and Osborne M.R. N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis 20 (1999) 2003-2009
36. Phillips D.H. Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22 (2001) 839-849
37. Phillips D.H., Hewer A., Osborne M.R., Cole K.J., Churchill C., and Arlt V.M. Organ specificity of DNA adduct formation by tamoxifen and α-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment. Mutagenesis 20 (2005) 297-303
38. Powles T.J. Efficacy of tamoxifen as treatment of breast cancer. Semin. Oncol. 24 (1997) S1-54-S1-48
39. Rebbeck T.R., Troxel A.B., Wang Y., Walker A.H., Panossian S., Gallagher S., Shatalova E.G., Blanchard R., Bunin G., DeMichele A., Rubin S.C., Baumgarten M., Berlin M., Schinnar R., Berlin J.A., and Strom B.L. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl. Cancer Inst. 98 (2006) 1311-1320
40. Rubin G.L., Harrold A.J., Mills J.A., Falany C.N., and Coughtrie M.W.H. Regulation of sulphotransferase expression in the endometrium during the menstrual cycle, by oral contraceptives and during pregnancy. Mol. Hum. Reprod. 5 (1999) 995-1002
41. Stockholm Breast Cancer Study Group, Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J. Natl. Cancer Inst. 87 (1995) 645-651
42. Schlesinger C., Kamoi S., Ascher S.M., Kendell M., Lage J.M., and Silverberg S.G. Endometrial polyps: a comparison study of patients receiving tamoxifen within two control groups. Int. J. Gynecol. Pathol. 17 (1998) 302-311
43. Sharma M., Shubert D.E., Sharma M., Lewis J., McGarrigle B.P., Bofinger D.P., and Olsen J.R. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem. Biol. Interact. 146 (2003) 237-249
44. Shibutani S., Suzuki N., Terashima I., Sugarman S.M., Grollman A.P., and Pearl M.L. Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12 (1999) 646-653
45. Singh M.N., Stringfellow H.F., Parakaveidis E., Martin-Hirsch P.L., and Martin F.L. Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat. Rev. 33 (2007) 91-100
46. Swerdlow A.J., and Jones M.E. Tamoxifen treatment of breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Cancer Inst. 97 (2005) 375-384
47. Tannenbaum S.R. Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin. Oncol. 24 (1997) S1-8-S1-6
48. Tsuchiya Y., Nakajima M., and Yokoi T. Cytochrome P450-mediated metabolism of oestrogens and its regulation in human. Cancer Lett. 227 (2005) 115-124
49. van Leeuwen F.E., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrère C.H., Otter R., Schouten L.J., Damhuis R.A., Bontenbal M., Diepenhorst F.W., van den Belt-Dusebout A.W., and van Tinteren H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343 (1994) 448-452
50. Williams G.M., Iatropoulos M.J., Djordjevic M.V., and Kaltenberg O.P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14 (1993) 315-317